Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RADX vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: RADX 1 – 5 ACAD Matrix Metrics: RADX 0 – 10 ACAD

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RADX carries a Unified Composite Score of 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin), whereas ACAD carries 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin).

  • Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RADX vs ACAD
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
TTM Revenue $1.20B
Forward P/E 15.8x
Beta / 30D Vol 0.15β · 90% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $19.31 · SMA50: $20.80

6-Pillar Scorecard Institutional Category Breakdown (RADX 1 – 5 ACAD)

Columns: Metric · RADX · ACAD
1. Valuation Multiples ACAD
Forward P/E N/M 15.8x
Trailing P/E N/M 8.3x
PEG Ratio N/M N/M
EV / Revenue 0.8x 2.3x
2. Growth & Scale ACAD
Revenue Growth (YoY) -36.9% +22.8%
Earnings Growth (YoY) +0.0% -26.2%
TTM Revenue (USD) $13M $1.20B
Market Cap $10.6M $3.0B
3. Profitability & Quality ACAD
Gross Margin N/A 63.9%
Operating Margin -411.6% 10.2%
Net Profit Margin 0.0% 30.1%
Return on Equity (ROE) -174.7% 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) -$50M EBITDA $181M
Cash Flow Margin N/A 15.0%
Net Cash / Leverage $1.48 Book/Sh · -174.7% ROE $251M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RADX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 41.7% (6th %ile)
Put/Call OI Skew Thin ADR Chain 71.82x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity N/A 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RADX (0) vs ACAD (10)
Institutional Metric RADX ACAD Criterion Row Edge
Market Capitalization
Scale
$10.6M $3.0B Larger Scale ACAD
Trailing P/E Ratio
Valuation
N/M 8.3x Lower Multiple ACAD
Forward P/E Ratio
Valuation
N/M 15.8x Lower Multiple ACAD
Revenue Growth (YoY)
Growth
-36.9% +22.8% Higher Growth ACAD
Operating Margin (TTM)
Profitability
-411.6% 10.2% Higher Margin ACAD
Net Profit Margin
Profitability
0.0% 30.1% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
-174.7% 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
0% ($1–$16) 8% ($16–$31) Stronger Trend ACAD
Beta / 30D Volatility
Risk Regime
0.52β · 109% Vol 0.15β · 90% Vol Lower Realized Risk ACAD
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite ACAD
Trailing 12M Revenue (USD)
Operating Scale
$13M $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACAD +17.88 pp
RADX: -33.64% · ACAD: -15.76%
3M Horizon ACAD +31.87 pp
RADX: -74.16% · ACAD: -42.29%
6M Horizon ACAD +67.91 pp
RADX: -86.24% · ACAD: -18.33%
1Y Horizon ACAD +60.42 pp
RADX: -86.35% · ACAD: -25.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RADX vs ACAD. Trailing 12-month operating profitability (RADX -411.6% vs ACAD 10.2%) and valuation multiples (RADX N/M vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.

RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M
ACAD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.20B
Gross Margin63.9%
Op. Margin10.2%
ROE / Fwd P/E31.4% · 15.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 41.7%
IV Percentile 6th %ile
Put/Call OI Skew 71.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $18.67 · IV 48.0%

ACAD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,867)

Compare $1,867 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $17 / $16 Bull Put Spread

Sell 3x $17P · Buy 3x $16P · 32d

Net Entry $75 Credit
Max Credit / Yield +$75 (+33.3% RoM)
Max Risk / Buffer -10.3% Cushion ($225 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $20 / $17 Bear Put Spread

Buy 1x $20P · Sell 1x $17P · 32d

Net Entry $85 Debit
T+5d @ -5% Drop +$54 (+64%)
Max Risk / Buffer $85 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ RADX vs ACAD Key Questions & Quantitative Answers

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RADX carries a Unified Composite Score of 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin), whereas ACAD carries 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin). Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: RADX posts -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, RADX generates $13M in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, RADX deploys N/A (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

ACAD screens cheaper on headline valuation multiples. RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RADX (-174.7% ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk). By comparison, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.